WO2024021625A1 - 一种普拉克索昔萘酸盐的晶型a及其制备方法 - Google Patents

一种普拉克索昔萘酸盐的晶型a及其制备方法 Download PDF

Info

Publication number
WO2024021625A1
WO2024021625A1 PCT/CN2023/081207 CN2023081207W WO2024021625A1 WO 2024021625 A1 WO2024021625 A1 WO 2024021625A1 CN 2023081207 W CN2023081207 W CN 2023081207W WO 2024021625 A1 WO2024021625 A1 WO 2024021625A1
Authority
WO
WIPO (PCT)
Prior art keywords
crystal form
pramipexole
sodium
pramipexoxinafoate
xinafoate
Prior art date
Application number
PCT/CN2023/081207
Other languages
English (en)
French (fr)
Inventor
孙迎基
邢晓燕
王玉广
李铁军
刘善奎
Original Assignee
山东京卫制药有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 山东京卫制药有限公司 filed Critical 山东京卫制药有限公司
Publication of WO2024021625A1 publication Critical patent/WO2024021625A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
    • C07C65/11—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the invention belongs to the field of chemical medicine, and specifically relates to a crystal form A of pramipexoxinafoate and a preparation method thereof.
  • Parkinson's disease is a movement disorder of the nervous system. It is characterized by a progressive disease that affects movement and results in the loss of dopamine-producing brain cells, causing tremors in the hands, arms, legs, jaw and face and/or rigidity or stiffness of the limbs and trunk. Key symptoms include muscle stiffness, slow movement, resting tremor, and postural instability.
  • the molecular formula of pramipexole is C 11 H 17 N 3 S, and its chemical name is (S)-(-)-2-amino-6-(propylamino)-4,5,6,7-tetrahydrobenzothiazole.
  • the affinity of the S(-) isomer for the dopamine D2 receptor is approximately 8-10 times that of its R(+) isomer and 2 times that of the racemate.
  • the S(-) isomer of pramipexole is also significantly more effective in treating Parkinson's disease than the R(+) isomer and the racemate.
  • the chemical structural formula of pramipexole S(-) isomer is as follows:
  • Pramipexole is currently marketed mainly in oral dosage forms, such as ordinary immediate-release tablets and sustained-release tablets.
  • oral dosage forms such as ordinary immediate-release tablets and sustained-release tablets.
  • PD patients need to take long-term or even lifelong medication, and PD patients are accompanied by symptoms such as tremor, muscle stiffness, and bradykinesia, so oral administration brings serious inconvenience to PD patients and their caregivers. .
  • the present invention conducts research on pramipexole salt and unexpectedly finds that the solubility of pramipexole and xinafoate is significantly reduced compared to other acid saline salts after the salt formation of pramipexole and xinafoate, and further obtains a new crystal form of pramipexole xinafoate. It is prepared into a suspension injection, which has a good sustained-release effect through subcutaneous and intramuscular injection, and can maintain a stable and effective blood concentration for a long time.
  • the X-ray powder diffraction pattern of the pramipexoxinafoate crystal form A has diffraction peaks at 2 ⁇ (°) values at 7.80 ⁇ 0.20°, 10.64 ⁇ 0.20°, 22.67 ⁇ 0.20°, and 25.49 ⁇ 0.20°.
  • the X-ray powder diffraction pattern of the crystal form A has diffraction at 2 ⁇ values of 10.76 ⁇ 0.20°, 13.95 ⁇ 0.20°, 19.15 ⁇ 0.20°, 24.64 ⁇ 0.20°, 26.39 ⁇ 0.20°, and 27.26 ⁇ 0.20°. peak.
  • the present invention provides a method for preparing the above crystal form, which includes: adding pramipexole xinafoate to an organic solvent, heating to reflux and dissolving, filtering, cooling to room temperature, stirring (2 to 4 hours), and filtering, Dry until dry (dry under reduced pressure at 40-50°C).
  • the organic solvent is selected from one or more alcoholic solvents or a combination thereof and water.
  • the organic solvent is selected from one or more of anhydrous methanol, anhydrous ethanol, 95% ethanol (V/V), isopropyl alcohol, benzyl alcohol, or a combination thereof with water.
  • Anhydrous ethanol is preferred.
  • the present invention also provides a pharmaceutical sustained-release preparation of pramipexole, using the crystal form A of the pramipexole xinafoate salt of the present invention as the main active ingredient of the drug.
  • the drug sustained-release preparation can be capsules, tablets, oral suspensions, or suspension injections.
  • the pharmaceutical preparation Agents also include analgesics, such as one or more of benzyl alcohol, chlorobutanol, procaine hydrochloride, and lidocaine.
  • the suspension liquid preparation of the present invention also contains one or more of a wetting agent, a suspending agent, a stabilizer, a pH regulator, and an osmotic pressure regulator.
  • the wetting agent is selected from one or more of polysorbate, polyoxyethylene castor oil, poloxamer 188, and lecithin;
  • the suspending agent is selected from PVP, gelatin, and methylcellulose. , sodium carboxymethylcellulose, one or more of polyethylene glycol;
  • the stabilizer is selected from one or more of sodium sulfite, sodium bisulfite, sodium metabisulfite, sodium thiosulfate, and EDTA sodium salt.
  • the pH regulator is selected from one or more of hydrochloric acid, sodium hydroxide, sodium bicarbonate, acetic acid-sodium acetate buffer, citric acid and sodium citrate buffer;
  • the osmotic pressure regulator Selected from sodium chloride and/or glucose.
  • the particle size of crystal form A of pramipexoxinafoate is D 10 : 0.1 to 1 ⁇ m; D 50 : 0.5 to 5 ⁇ m; D 90 : 2 to 30 ⁇ m.
  • Preferable crystal particle diameters D 10 0.1 to 0.5 ⁇ m; D 50 : 0.5 to 1 ⁇ m; D 90 : 2 to 10 ⁇ m.
  • the preparation method of the suspension liquid preparation of the present invention is as follows:
  • the pramipexoxinafoate salt of the present invention has stable crystal form and no hygroscopicity, which is beneficial to preparation development.
  • the crystal provided by the invention is stable and has low hygroscopicity.
  • the preparation method provided by the invention is simple, the solvent is cheap and easy to obtain, the crystallization conditions are mild, and it is suitable for industrial production.
  • Figure 1 is a 1 H-NMR spectrum of the crystal obtained in Example 1.
  • Figure 2 is the MS (ESI+) spectrum of the crystal prepared in Example 1.
  • Figure 3 is the MS (ESI-) spectrum of the crystal prepared in Example 1.
  • Figure 4 is an X-ray powder diffraction pattern of the crystal obtained in Example 1.
  • Figure 5 is a differential scanning calorimetry pattern of the crystal prepared in Example 1.
  • Figure 6 is the infrared spectrum of the crystal prepared in Example 1.
  • Figure 7 is an X-ray powder diffraction pattern of the crystal obtained in Example 3.
  • Figure 8 is an X-ray powder diffraction pattern of the crystal obtained in Example 4.
  • pramipexoxinafoate (12.6mmol, 7.4g) and 100mL of absolute ethanol into the reaction bottle, stir, heat to reflux, dissolve, filter, bring the filtrate to room temperature, continue stirring for 2 hours, filter, and use for filter cake Wash with absolute ethanol and dry under reduced pressure at 40-50°C to obtain 6.58g of pramipexoxinafoate crystal form A, with a yield of 88.92%.
  • the structure of pramipexoxinafoate was analyzed using 1 H-NMR and MS.
  • the 1 H-NMR spectrum of the crystal is shown in Figure 1; the MS spectrum is shown in Figures 2 and 3; the X-ray powder diffraction spectrum is shown in Figure 4; the differential scanning calorimetry spectrum is shown in Figure 5; infrared spectrum The diagram is shown in Figure 6.
  • pramipexoxinafoate (1mmol, 0.59g) and 6 mL of anhydrous methanol into the reaction flask, stir, heat to reflux, dissolve, filter, bring the filtrate to room temperature, continue stirring for 4 hours, filter, and filter the filter cake with Wash with water and methanol, and dry under reduced pressure at 40-50°C until dry, to obtain 0.27g of pramipexoxinafoate crystal form A product, with a yield of 45.76%.
  • pramipexole xinafoate crystal forms A, B, and C use an airflow pulverizer respectively, set the feed speed to 400 rpm, the feed pressure to 2.1 to 2.3 bar, and adjust the pulverization pressure. Grind until the particle size distribution D90 is between 2 and 10um
  • each crystalline API and surfactant are fully moistened with an appropriate amount of water for injection, then added to the concentrated tank, and sterilized at 121°C for 15 minutes.
  • Example 6 investigates the formulation stability of pramipexole xinafoate crystal forms A, B, and C.
  • prescription 1 (pramipexole xinafoate crystal form A)
  • prescription 2 (pramipexole xinafoate crystal form B)
  • prescription 3 (pramipexole xinafoate crystal form C) were subjected to accelerated conditions respectively.
  • the conditions temperature: 40°C ⁇ 2°C; humidity: 75% ⁇ 5%
  • the content, related substances, particle size distribution and particle aggregation and other indicators were inspected, and the inspections were conducted at the 3rd and 6th months respectively.
  • impurity A is as follows:
  • the content of pramipexole xinafoate was determined by HPLC, and the chromatographic conditions were as follows:
  • the sample prepared using crystal form A has the best stability.
  • the impurity A increased significantly during the stability investigation of prescription 2.
  • the crystal form used in prescription 3 is easily damaged during the crushing process. Moisture absorption causes aggregation, and obvious aggregation occurred during the stability investigation.
  • the crystal form A prepared by the present invention has obvious advantages.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

一种普拉克索昔萘酸盐（(S)-(-)-2-氨基-6-(丙氨基)-4,5,6,7-四氢苯并噻唑二1-羟基萘甲酸盐）的晶型A及其制备方法。所述普拉克索昔萘酸盐结构式如下：（I）。所述普拉克索昔萘酸盐晶型A的X-射线粉末衍射图谱2θ(°)值在7.80±0.20°、10.64±0.20°、10.76±0.20°、13.95±0.20°、19.15±0.20°、22.67±0.20°、24.64±0.20°、25.49±0.20°、26.39±0.20°、27.26±0.20°处有衍射峰。使用所述晶型A制备的混悬型注射液具有明显的缓释效果。

Description

一种普拉克索昔萘酸盐的晶型A及其制备方法 技术领域
本发明属于化学医药领域，具体涉及一种普拉克索昔萘酸盐的晶型A及其制备方法。
背景技术
帕金森病是神经系统的运动系统障碍。其特征为进行性疾病，其影响运动并导致产生多巴胺的脑细胞的损失，引起手、臂、腿、颌和脸的震颤和/或四肢和躯干的强直或僵硬。主要症状包括肌肉僵硬运动缓慢、静止震颤和姿势不稳定。
普拉克索分子式为C11H17N3S，化学名称为(S)-(-)-2-氨基-6-(丙氨基)-4,5,6,7-四氢苯并噻唑，其S(-)异构体对多巴胺D2受体的亲和力约是其R(+)异构体的8-10倍，是外消旋体的2倍。普拉克索S(-)异构体对帕金森病的治疗效果也明显优于R(+)异构体和外消旋体。普拉克索S(-)异构体的化学结构式如下：
目前，文献报道较多的是普拉克索二盐酸盐及普拉克索二盐酸盐一水合物的晶型，国际专利申请WO2007054970中公开了盐酸普拉克索的晶型Ⅰ、晶型Ⅱ、晶型Ⅲ和晶型Ⅳ。中国专利CN111212640公开了普拉克索双羟萘酸盐的晶型1、晶型2、晶型3和晶型4。然而普拉克索二盐酸盐及普拉克索二盐酸盐一水合物和普拉克索双羟萘酸盐稳定性差、引湿性强，不利于制剂开发。
普拉克索目前上市的主要是口服剂型，如普通速释片及缓释片。但是由于普拉克索的半衰期较短，且PD患者需要长期甚至终身服药，同时PD患者伴随的震颤、肌僵直和运动迟缓等症状使得口服给药给PD患者及其护理人员带来了严重的不便。
发明内容
本发明对普拉克索盐进行了研究，意外发现普拉克索与昔萘酸成盐后相对于其它酸式盐水溶性显著降低，并进一步获得了普拉克索昔萘酸盐的新晶型，将其制备成混悬剂注射剂，通过皮下和肌肉注射具有良好的缓释效果，可以长时间维持稳定有效的血药浓度。
本发明具体技术方案如下：
普拉克索昔萘酸盐的晶型A，所述普拉克索昔萘酸盐结构式如下：
所述普拉克索昔萘酸盐晶型A的X-射线粉末衍射图谱2θ(°)值在7.80±0.20°、10.64±0.20°、22.67±0.20°、25.49±0.20°处有衍射峰。
进一步的，所述的晶型A的X射线粉末衍射图谱在2θ值10.76±0.20°、13.95±0.20°、19.15±0.20°、24.64±0.20°、26.39±0.20°、27.26±0.20°处有衍射峰。
本发明所述的普拉克索昔萘酸盐的晶型A的PXRD谱图(使用Cu-Kα辐射)如附图1所示，其具有如下特征：
表1
另一方面，本发明提供了上述晶型的制备方法，包括：将普拉克索昔萘酸盐加入有机溶剂中，加热至回流溶解，过滤，降至室温，搅拌(2～4h)，过滤，干燥至干(40～50℃减压干燥)。
更进一步地，所述的有机溶剂选自醇类溶剂中的一种或几种或其与水的组合。
更进一步地，所述的有机溶剂选自无水甲醇、无水乙醇、95％乙醇(V/V)、异丙醇、苯甲醇、中的一种或几种，或其与水的组合。优选无水乙醇。进一步的，本发明还提供了一种普拉克索的药物缓释制剂，采用本发明所述普拉克索昔萘酸盐的晶型A为药物主要活性成分。
所述药物缓释制剂可以为胶囊剂、片剂、口服混悬液、混悬注射剂。
为了提高所述药物制剂的顺应性，降低混悬液体制剂注射时带来的不适感，所述药物制 剂还包括止痛剂，例如苯甲醇、三氯叔丁醇、盐酸普鲁卡因、利多卡因中的一种或几种。
本发明所述的混悬液体制剂，还包含润湿剂、助悬剂、稳定剂、pH调节剂、渗透压调节剂中的一种或几种。
优选的所述润湿剂选自聚山梨酯、聚氧乙烯蓖麻油、泊洛沙姆188、卵磷脂中的一种或几种；所述助悬剂选自PVP、明胶、甲基纤维素、羧甲基纤维素钠、聚乙二醇中的一种或几种；所述稳定剂选自亚硫酸钠、亚硫酸氢钠、焦亚硫酸钠、硫代硫酸钠、EDTA钠盐中的一种或几种；所述的pH调节剂选自盐酸、氢氧化钠、碳酸氢钠、醋酸-醋酸钠缓冲液、柠檬酸和柠檬酸钠缓冲液中的一种或几种；所述的渗透压调节剂选自氯化钠和/或葡萄糖。
本发明所述的药物缓释制剂中，普拉克索昔萘酸盐的晶型A的粒径为D10：0.1～1μm；D50：0.5～5μm；D90：2～30μm。优选晶体的粒径D10：0.1～0.5μm；D50：0.5～1μm；D90：2～10μm。
本发明的混悬液体制剂制备方法如下：
1)普拉克索昔萘酸盐的晶型A微粉至一定的粒度分布。
2)微粉后的普拉克索昔萘酸盐的晶型A与润湿剂加入适量的注射用水充分润湿后加入浓配罐，121℃灭菌15min。
3)其他辅料加入辅料罐，加入适量注射用水溶解后除菌过滤。
4)浓配罐中的药液和辅料罐中的辅料液中加入稀配罐，加入注射用水定容得混悬药液。
5)混悬药液灌装于安瓿中密封即得。
本发明优点：
本发明所述普拉克索昔萘酸盐晶型稳定，无引湿性，有利于制剂开发。本发明提供的晶体稳定，吸湿性小，本发明提供的制备方法简单，溶剂廉价易得，结晶条件温和，适合工业化生产。
附图说明
图1实施例1得到的晶体的1H-NMR图谱。
图2实施例1制备得到的晶体MS(ESI+)图谱。
图3实施例1制备得到的晶体MS(ESI-)图谱。
图4实施例1得到的晶体的X-射线粉末衍射图谱。
图5实施例1制备得到的晶体的差示扫描量热图谱。
图6实施例1制备得到的晶体的红外光谱图。
图7实施例3得到的晶体的X-射线粉末衍射图谱。
图8实施例4得到的晶体的X-射线粉末衍射图谱。
具体实施方式
下面结合具体实施方式和范例性实施例对本发明作进行详细说明，但这些说明并不能理解为对本发明的任何限制。本领域技术人员理解，在不偏离本发明精神和范围的情况下，可以对本发明技术方案及其实施方式进行多种等价替换，修饰或改进，这些均落入本发明的范围内。本发明的保护范围以所附权利要求为准。具体实施例阐述如下：
实施例1普拉克索昔萘酸盐晶型A的制备
将普拉克索昔萘酸盐(12.6mmol，7.4g)和无水乙醇100mL加入到反应瓶中，搅拌，加热至回流，溶解，过滤，滤液降至室温，继续搅拌2h，过滤，滤饼用无水乙醇洗涤，40～50℃减压干燥至干，得普拉克索昔萘酸盐晶型A 6.58g，收率88.92％。使用1H-NMR和MS分析普拉克索昔萘酸盐结构。1H-NMR(600MHz)化学位移记录在(所有值以ppm计)8.757(d，2H),8.241(d，2H),7.803(d，2H),7.743(d，2H)，7.563(d，2H)，7.473(t，2H)，7.193(d，2H),6.837(s，2H)，3.4383(s，1H),2.980(s，3H)，2.603(m，1H)，2.540(m，1H),2.500(m，1H)，2.168(m，1H),1.823(m，1H),1.644(m，2H)，0.937(t，3H)。MS(ESI)：212.0(正离子模式)，186.9(负离子模式)。
晶体的1H-NMR图谱如图1所示；MS图谱如图2和图3所示；X-射线粉末衍射图谱如图4所示；差示扫描量热图谱如图5所示；红外光谱图如图6所示。
实施例2普拉克索昔萘酸盐晶型A的制备
将普拉克索昔萘酸盐(1mmol，0.59g)和无水甲醇6mL加入到反应瓶中，搅拌，加热至回流，溶解，过滤，滤液降至室温，继续搅拌4h，过滤，滤饼用无水甲醇洗涤，40～50℃减压干燥至干，得普拉克索昔萘酸盐晶型A产品0.27g，收率45.76％。
实施例3普拉克索昔萘酸晶型B样品的制备
将普拉克索昔萘酸盐(10mmol，5.88g)和二甲亚砜5mL加入到反应瓶中，搅拌溶解，向上述溶液中滴加注射用水30ml，析出固体，室温搅拌2h，过滤，滤饼用适量注射用水洗涤，40～50℃减压干燥至干，得普拉克索昔萘酸盐晶型B样品4.82g，收率81.97％。晶体的X-射线粉末衍射图谱如图7所示。
实施例4普拉克索昔萘酸盐晶型C样品的制备
将普拉克索昔萘酸盐(10mmol，5.88g)和甲醇59mL加入到反应瓶中，搅拌，加热至回流，溶解，降温至50℃滴加丙酮120ml，过滤，滤液降至室温，继续搅拌3h，过滤，滤饼用适量丙酮洗涤，40～50℃减压干燥至干，得普拉克索西萘酸盐3.41g，收率57.99％。晶体的X-射线粉末衍射图谱如图8所示。
实施例5普拉克索昔萘酸盐晶型A、B、C制备普拉克索混悬型注射液
一、处方
表2处方用量表
二、工艺
1、原料前处理
普拉克索昔萘酸盐晶型A、B、C原料药分别使用气流粉碎机，设定进料速度400rpm，进料压力2.1～2.3bar，调整粉碎压力。粉碎至的粒度分布D90在2～10um
粉碎过程中，发现处方3即普拉克索昔萘酸盐晶型C的原料药粉碎后吸湿较严重，微粉后的原料易结块。
2、浓配液的配制
微粉后的各晶型原料药与表面活性剂加入适量的注射用水充分润湿后加入浓配罐，121℃灭菌15min。
3、辅料液的配制
其他辅料加入辅料罐，加入适量注射用水溶解后除菌过滤。
4、定容
浓配罐中的药液和辅料罐中的辅料液中加入稀配罐，加入注射用水定容得混悬药液。
5、灌装
混悬药液2ml灌装于2ml安瓿中密封即得。
实施例6考察普拉克索昔萘酸盐晶型A、B、C的处方稳定性。
分别将处方1(普拉克索昔萘酸盐晶型A)、处方2(普拉克索昔萘酸盐晶型B)和处方3(普拉克索昔萘酸盐晶型C)样品于加速条件下(温度：40℃±2℃；湿度：75％±5％)进行含量、有关物质、粒度分布和粒子聚集等指标的考察，分别于第3个月和第6个月进行考察。
杂质A结构如下：
有关物质使用HPLC法进行检测，色谱条件如下：
色谱柱：Waters Xselect HSS PFP 4.6mm×250mm，5μm。检测波长：262nm。流速：1.0ml/min。柱温：30℃。进样量：10μl。流动相A：0.01％磷酸，流动相B：乙腈，梯度洗脱程序：
普拉克索昔萘酸盐含量采用HPLC法，色谱条件如下：
色谱柱：苯基键合硅胶色谱柱(推荐使用：Agilent ZORBAX SB-Phenyl，4.6mm×150mm，3.5μm)。流动相：甲醇-0.1％甲酸溶液(35:65)。检测波长：262nm。流速：1.5ml/min。柱温：30℃。进样量：10μl。结果如表3所示。
表3
结果显示，不同晶型制备样品稳定性差别较大，其中使用晶型A制备的样品稳定性最好，处方2稳定性考察中杂质A增加明显，处方3使用的晶型在粉碎过程中易因吸湿产生聚集，并且在稳定性考察过程中产生明显的聚集。本发明制备的晶型A具有明显的优势。

Claims (10)

  1. 普拉克索昔萘酸盐的晶型A，其特征在于所述普拉克索昔萘酸盐结构式如下：所述普拉克索昔萘酸盐晶型A的X-射线粉末衍射图谱2θ(°)值在7.80±0.20°、10.64±0.20°、22.67±0.20°、25.49±0.20°处有衍射峰。
  2. 根据权利要求1所述的普拉克索昔萘酸盐的晶型A，其特征在于所述的晶型A的X射线粉末衍射图谱进一步在2θ值10.76±0.20°、13.95±0.20°、19.15±0.20°、24.64±0.20°、26.39±0.20°、27.26±0.20°处有衍射峰。
  3. 根据权利要求2所述的普拉克索昔萘酸盐的晶型A，其特征在于所述的晶型A的X射线粉末衍射图谱进一步在2θ值11.41±0.20°、11.79±0.20°、19.50±0.20°、21.37±0.20°处有衍射峰。
  4. 权利要求1-3任一项所述普拉克索昔萘酸盐的晶型A的制备方法，其特征在于采用如下方法制备而成：
    将普拉克索昔萘酸盐加入有机溶剂中，加热至回流溶解，过滤，降至室温，搅拌2～4h，过滤，干燥，所述的有机溶剂选自醇类溶剂中的一种或几种，或者其与水的组合。
  5. 根据权利要求4所述的普拉克索昔萘酸盐的晶型A的制备方法，其特征在于所述的有机溶剂选自无水甲醇、无水乙醇、95％乙醇、异丙醇、苯甲醇中的一种或几种或其与水的组合。
  6. 一种普拉克索的药物缓释制剂，其特征在于以权利要求1-3任一项所述普拉克索昔萘酸盐的晶型A为药物主要活性成分。
  7. 根据权利要求6所述的药物缓释制剂，其特征在于所述药物缓释制剂为胶囊剂、片剂、口服混悬液、混悬注射剂。
  8. 根据权利要求7所述的药物缓释制剂，其特征在于所述药物缓释制剂为混悬注射剂，包含润湿剂、助悬剂、稳定剂、pH调节剂、渗透压调节剂、止痛剂中的一种或几种。
  9. 根据权利要求8所述的药物缓释制剂，其特征在于所述润湿剂选自聚山梨酯、聚氧乙烯蓖麻油、泊洛沙姆188、卵磷脂中的一种或几种；所述助悬剂选自PVP、明胶、甲基纤维素、羧甲基纤维素钠、聚乙二醇中的一种或几种；所述稳定剂选自亚硫酸钠、亚硫酸氢钠、焦亚硫酸钠、硫代硫酸钠、EDTA钠盐中的一种或几种；所述的pH调节剂选自盐酸、氢氧化钠、碳酸氢钠、醋酸-醋酸钠缓冲液、柠檬酸和柠檬酸钠缓冲液中的一种或几种；所述的 渗透压调节剂选自氯化钠和/或葡萄糖；所述止痛剂选自苯甲醇、三氯叔丁醇、盐酸普鲁卡因、利多卡因中的一种或几种。
  10. 权利要求1-3任一项所述普拉克索昔萘酸盐的晶型A在制备治疗帕金森病药物中的应用。
PCT/CN2023/081207 2022-07-26 2023-03-14 一种普拉克索昔萘酸盐的晶型a及其制备方法 WO2024021625A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210887655.XA CN115141161B (zh) 2022-07-26 2022-07-26 一种普拉克索昔萘酸盐的晶型a及其制备方法
CN202210887655.X 2022-07-26

Publications (1)

Publication Number Publication Date
WO2024021625A1 true WO2024021625A1 (zh) 2024-02-01

Family

ID=83413412

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/081207 WO2024021625A1 (zh) 2022-07-26 2023-03-14 一种普拉克索昔萘酸盐的晶型a及其制备方法

Country Status (2)

Country Link
CN (1) CN115141161B (zh)
WO (1) WO2024021625A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115141161B (zh) * 2022-07-26 2023-03-28 山东京卫制药有限公司 一种普拉克索昔萘酸盐的晶型a及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070059717A1 (en) * 2005-09-15 2007-03-15 Baylor Research Institute Systemic lupus erythematosus diagnostic assay
WO2007054970A2 (en) * 2005-10-25 2007-05-18 Alembic Limited Novel polymorphic forms of (s)-(-)-2-amino-6-(n- propylamino) 4,5,6,7- tetrahydrobenzothiazole
CN107540632A (zh) * 2016-06-27 2018-01-05 江苏神龙药业股份有限公司 一种普拉克索单盐酸盐的新晶型及其制备方法
CN111212640A (zh) * 2017-08-17 2020-05-29 顾自强 单胺抗帕金森药物的双羟萘酸盐、其制备方法及其用途
CN115141161A (zh) * 2022-07-26 2022-10-04 山东京卫制药有限公司 一种普拉克索昔萘酸盐的晶型a及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107382904A (zh) * 2017-08-17 2017-11-24 山东新华制药股份有限公司 普拉克索的一种新晶型及其制备方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070059717A1 (en) * 2005-09-15 2007-03-15 Baylor Research Institute Systemic lupus erythematosus diagnostic assay
WO2007054970A2 (en) * 2005-10-25 2007-05-18 Alembic Limited Novel polymorphic forms of (s)-(-)-2-amino-6-(n- propylamino) 4,5,6,7- tetrahydrobenzothiazole
CN107540632A (zh) * 2016-06-27 2018-01-05 江苏神龙药业股份有限公司 一种普拉克索单盐酸盐的新晶型及其制备方法
CN111212640A (zh) * 2017-08-17 2020-05-29 顾自强 单胺抗帕金森药物的双羟萘酸盐、其制备方法及其用途
CN115141161A (zh) * 2022-07-26 2022-10-04 山东京卫制药有限公司 一种普拉克索昔萘酸盐的晶型a及其制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ELSNER, JAN ET AL.: "Pharmacophore-Guided Drug Discovery Investigations Leading to Bioactive 5-Aminotetrahydropyrazolopyridines. Implications for the Binding Mode of Heterocyclic Dopamine D3 Receptor Agonists", JOURNAL OF MEDICINAL CHEMISTRY, vol. 48, no. 18, 11 August 2005 (2005-08-11), pages 5771 - 5779, XP002520691, DOI: 10.1021/JM0503805 *
XIURONG HU, SHEN JIN, SUXIANG WU, JIAJIA WU: "Preparation and Characterization of Form B of Pramipexole Dihydrochloride", CHINESE JOURNAL OF MODERN APPLIED PHARMACY, vol. 32, no. 9, 22 September 2015 (2015-09-22), pages 1086 - 1090, XP093132644, DOI: 10.13748/j.cnki.issn1007-7693.2015.09.014 *

Also Published As

Publication number Publication date
CN115141161B (zh) 2023-03-28
CN115141161A (zh) 2022-10-04

Similar Documents

Publication Publication Date Title
WO2024021626A1 (zh) 一种普拉克索昔萘酸盐及其药物缓释制剂
CA2728541C (en) Crystalline forms of thiazolidinedione compound and its manufacturing method
WO2024021625A1 (zh) 一种普拉克索昔萘酸盐的晶型a及其制备方法
KR102572035B1 (ko) 무정형 형태의 빌란테롤 트리페나테이트 및 이의 제조방법
WO2022042643A1 (zh) 卡利拉嗪药用盐及其晶型、制备方法和应用
EP2253619B1 (en) Amine salt of carbostyril derivative
CN111454271B (zh) 一种吡咯烷羧酸类化合物的钠盐、结晶形式及其制备方法
JP7453475B2 (ja) オラパリブシュウ酸共結晶及びその医薬的使用
CN104447682A (zh) 比拉斯汀化合物
CN106963766B (zh) 一种氮杂螺酮类药物组合物及其制备方法
CN114644642B (zh) 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物
EP3985009B1 (en) B crystal form of tetrahydrothienopyridine compound, preparation method therefor, composition and application
CN111233877B (zh) 一种加兰他敏帕莫酸盐及其制备方法
CN105566316A (zh) 二苯并喹嗪类化合物实体及其用途
CN104447683A (zh) 一种稳定的比拉斯汀化合物
CN103845332A (zh) 一种达沙替尼药用组合物及其制备方法
CN109970678B (zh) 4-苯基噻唑衍生物无定形及其制备方法和用途
KR20110011409A (ko) 피오글리타존 칼륨염의 결정다형, 이의 제조방법 및 이를 함유한 약학조성물
TWI449704B (zh) 嗎啡喃衍生物之結晶、其製造方法、及使用其之醫藥組成物
CN112076190A (zh) 一种含有难溶性噻吩并吡啶组合物的固体制剂及制备方法
WO2022241983A1 (zh) 一种左酮咯酸的药物组合物及其制备方法
CN105985252B (zh) 一种门冬氨酸鸟氨酸晶型iv及其制备方法
CN106397410B (zh) 5-羟色胺受体激动剂及其制备方法和用途
CN103570669B (zh) 脑靶向o-去甲基文拉法辛酚酯类前药及制备方法和用途
CN115244046B (zh) 一种阿哌沙班的尿素共晶及其制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23844843

Country of ref document: EP

Kind code of ref document: A1